Denali Therapeutics Inc.
For the period ended Nov 3, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 3, 2026 · Filed Nov 3, 2026
Use the contents to explore the available documents and sections.
DNLI$20.07+1.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · IND-ENABLING STAGE PROGRAMS
IND-ENABLING STAGE PROGRAMS
Denali has multiple additional programs in the investigational new drug (IND)-enabling stage, including DNL111 (ETV:GCase) for Parkinson's disease and Gaucher disease; DNL622 (ETV:IDUA) for MPS I; and DNL422 (OTV:SNCA) for Parkinson's disease.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.